Where Gay Love Is Illegal: Documenting LGBTI Stories of Discrimination & Survival from Around the World

Almost 2.8 billion people live in countries where identifying as lesbian, gay, transgender, bisexual and intersex could lead to imprisonment, corporal punishment or even death.

What began as a photo based project by award-winning photographer and human rights activist Robin Hammond developed into a space where people can share stories of discrimination and survival. It is a stand against discrimination, persecution, and violence, by a people who cannot and will not be anything other than the way they were born–a people who refuse to be silenced.

Please click here for the NY Times article.

Please click here to read more about Where Gay Love is Illegal, A Witness Change Project.

 

Washington D.C. Is Proof That Needle Exchanges Save Lives and Money

Washington, D.C. has a higher AIDS diagnosis rate than any U.S. state, with about 2.4 percent of residents living with HIV/AIDS. Just over 14 percent of those cases are linked to injection drug use.
But until 2007, there was a federal ban on using D.C.’s municipal funds for needle exchange programs, an outreach technique that reduces disease spread and can channel vital health and addiction services to drug users. When Congress lifted the ban, public health scientists were eager to see if needle exchanges would stem the tide of new HIV cases in the district.
Thanks to a new study that followed the first two years of such needle exchange programs in D.C., the verdict is in: By funding the exchanges, lawmakers helped avert at least 120 new HIV cases in the District in the first 24 months, saving an estimated $44 million in lifetime costs for HIV/AIDS care.

Please click here for full article.

HIV-preventing Drug Holds up Under Study

Truvada, a daily pill that holds the hope of eliminating the risk of contracting HIV, appears to be living up to its promise.

In the first real-world study of the prescription drug, Kaiser researchers found no new HIV infections among the more than 650 people they followed over nearly three years, beginning just after the drug was approved by the U.S. Food and Drug Administration in 2012.

Please click here to see full article.